Business Wire

CQN-MN-DATASITE

24.3.2020 15:24:12 CET | Business Wire | Press release

Share
CORRECTING and REPLACING Merrill Corporation Announces Rebrand to Datasite

Second paragraph, second sentence of release should read: The company’s due diligence application, formerly known as DatsiteOne Diligence, is now Datasite Diligence™, and its application for optimizing the early stage asset marketing process, formerly known as DatasiteOne Marketing, is now Datasite Outreach™ (instead of The company’s due diligence application, formerly known as DatsiteOne Diligence, is now Datasite® Diligence, and its application for optimizing the early stage asset marketing process, formerly known as DatasiteOne Marketing, is now Datasite® Outreach).

The corrected release reads:

MERRILL CORPORATION ANNOUNCES REBRAND TO DATASITE

New name reflects the company’s transformation and focus on using technology to drive success across the entire M&A lifecycle

Merrill Corporation, the leading technology provider for global mergers and acquisitions (M&A) professionals, today announced its corporate rebrand to Datasite. The new brand identity was created to better reflect the completion of the company’s 2018 digital transformation, which included divesting its legacy financial printing business, to focus on its global, SaaS-based technology platform for the M&A community.

In addition to a fresh company name, logo, and website, Datasite has also updated the branding of its core applications. The company’s due diligence application, formerly known as DatsiteOne Diligence, is now Datasite Diligence™, and its application for optimizing the early stage asset marketing process, formerly known as DatasiteOne Marketing, is now Datasite Outreach™.

“This is a major milestone in our company’s history,” said Rusty Wiley, CEO of Datasite. “We’ve evolved into an agile, global fintech software company and the Datasite name better represents our mission to lead the M&A industry beyond the virtual data room to a digitally-enabled future across the entire M&A lifecycle.”

In 2019, Datasite’s revenue increased by more than 30% as it facilitated more than 10,000 deals annually. To accommodate this growth, the company has moved its global headquarters from St. Paul, where it has been for 52 years, to the Baker Center in downtown Minneapolis, continuing its longstanding investment in the Twin Cities.

“As we continue to scale for growth, our commitment to the Twin Cities remains unchanged,” said Wiley. “We’re proud to have our global headquarters in Minneapolis and look forward to drawing from the area’s talented and diverse workforce.”

The new space can accommodate over 450 employees and is expected to bring additional jobs across finance, technology, and service to the region. Datasite currently employs more than 750 individuals in 25 locations across 13 countries.

At 80,000 square feet, the new headquarters replaces the St. Paul and North Loop offices, bringing together Datasite’s sales, service, product, marketing, finance, legal, IT and HR teams – the highest number of employees operating under one roof in the company’s history. The integrated design for the headquarters was modeled after the success of Datasite’s New York, London and Hong Kong locations.

To learn more about Datasite’s history and new global corporate headquarters, please visit: www.datasite.com

About Datasite

Datasite, formerly known as Merrill Corporation, is a leading SaaS provider for the M&A industry, empowering dealmakers around the world with the tools they need to succeed across the entire deal lifecycle. For more information, visit www.datasite.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye